Ranbaxy loses early bid to block generic competition
This article was originally published in Scrip
Ranbaxy has suffered an early setback in its challenge to the FDA's decision to revoke tentative approvals for its ANDAs for generic versions of AstraZeneca's Nexium (esomeprazole magnesium) and Roche's Valcyte (valganciclovir hydrochloride), after a US court declined to hold back competition for the products.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.